Decoding PK/PD Analysis: How Pharmacokinetics and Pharmacodynamics Shape Drug Development
Effective pharmacokinetics/pharmacodynamics (PK/PD) analysis during drug development requires inputs from several complementary disciplines. In most cases, PD assays are performed by pharmacological laboratories, while PK data analysis is conducted in DMPK laboratories. Moreover, in certain situations, pharmacokinetic data is not even determined in the same animals employed in pharmacodynamic assays. Rather, PK and PD data might be obtained independently in different laboratories and at different timeframes. In different timeframes, generating and supporting data may happen in isolation and require downstream evaluation and integration of data.
Ideally, when PK/PD assays are developed and conducted, the interpretation of generated data should be performed by pharmacology and DMPK experts with relevant inputs from various departments. Hence, the resulting report includes data integrated by different experts and addresses the questions and issues posed before beginning the study. The primary goal of early drug discovery and development is to identify promising compounds and develop safe yet effective doses. Integrating PK/PD data early in drug development can help select potential compounds and create a roadmap for efficient clinical development. The current article discusses the influence of PK/PD analysis in shaping drug development.
PK/PD assays for accelerating drug discovery and development
PK/PD analysis is a valuable tool for integrating quantitative data on pharmacologic properties with drug pharmacokinetics. Rational study design considers the causal relationship between drug exposure and therapeutic activity. This interconnectedness is generally complex. Hence, designing robust preclinical evaluations is critical to providing information for building relevant PK/PD models. Besides, as data becomes available, researchers can employ an iterative approach and refine the entire process. The output is an ultimate predictive system that considers all necessary requirements for enhanced efficacy.
A PK/PD assay offers an efficient approach to drug development. This method can help understand drug action and identify optimal compounds. Using PK/PD data early in drug development can reduce animal use, predict dose ranges, estimate the therapeutic index, and shorten development timelines. PK/PD assays integrate data from multiple studies based on drug and disease understanding. Hence, drug discovery and development is a model-building initiative where new knowledge is continuously updated and combined with prior knowledge to enhance decision-making and developmental strategy.
Must Read: The Importance of Cytokine Analysis in Biomedical Research
Scientists can establish confidence and optimize PK/PD experiments by using a reference tool or compound for which external or internal data is available. In cases when these data are missing, drug developers should ideally invest adequate time and resources to generate complete data packages with a reference compound before starting testing of study compounds. The initial goal at the early stages of drug development is to establish PK/PD principles. However, researchers and scientists should take adequate care while analyzing raw data, drawing preliminary conclusions, and establishing working hypotheses for subsequent testing. Ultimately, the final goal of working with a tool or reference compound is to comprehend the reasons behind a response, i.e., the connection between the pharmacodynamic readout and drug concentration.
Besides, researchers should ideally develop a PK/PD model using relevant matrices, such as plasma/blood or target tissue, that would generate a clear and well-defined dose-response relationship. After verifying the PK/PD model against a suitable tool compound, scientists should establish whether the reference compound data can be extrapolated to subsequent molecules.
As a drug product moves into the development stage, a deep understanding of the PK/PD characteristics of the lead compound will form the basis for PK analysis, anticipate the drug therapeutic index, and help identify efficacious doses for clinical studies. Multiple factors are necessary for utilizing the generated PK/PD data. The dataset should include the entire effect vs. time and concentration vs. time profiles, consider unbound concentrations, and integrate outcomes of new compounds from early-stage studies to later stages of clinical testing. By including a translational PK/PD profile validated with clinical outcomes, scientists can improve the capacity to treat and cure medical conditions.
Once PK/PD analysis is conducted in preclinical and other model systems, the generated data can help predict potential effects in clinical settings. Deciphering species uniqueness in PK data analysis, protein binding, biological target, and physiology can help translate preclinical information into the patient population.
The road ahead for PK/PD analysis
Today, drug developers and scientists have advanced bioanalytical approaches such as copy number variation assays, BA/BE evaluations, immunogenicity assessments, etc. Each method is unique and has different applications and advantages. A well-designed PK/PD assay helps in designing critical studies necessary to answer crucial scientific questions. Incorporating current experimental data into established PK/PD modules allows the development and refinement of frameworks and provides a deeper understanding of the exposure-effect relationship.
Most importantly, PK/PD assays facilitate the development of tailored experimental solutions to identify biological pathways relevant to the target compound. This iterative approach offers tailored solutions for a better understanding of drug action and the selection of optimal compounds for subsequent testing.
